In pediatric and young-adult patients with diffuse intrinsic pontine glioma, Vitanza et al. administered ex vivo gene-modified autologous T cells expressing a CAR against B7-H3 (CD276) via repeated intracerebroventricular infusions, demonstrating durable feasibility, manageable toxicity, and local immune activation with clinical benefit [46]. This evidence concerns the gene CD276 and diffuse intrinsic pontine glioma.